AstraZeneca PLC Company Information

AstraZeneca PLC's employee growth, exchange listings and data sources


Key Information

  • Name: AstraZeneca PLC
  • Ticker: AZN
  • Exchange: LSE
  • Founded: 1992
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£162.873b
  • Shares Outstanding: 1.55b
  • Website: https://www.astrazeneca.com

Number of Employees


Location

  • AstraZeneca PLC
  • 1 Francis Crick Avenue
  • Cambridge Biomedical Campus
  • Cambridge
  • Cambridgeshire
  • CB2 0AA
  • United Kingdom


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AZNNasdaqGS (Nasdaq Global Select)SPONSORED ADRUSUSDMay 1993
AZNC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 1993
AZNLSE (London Stock Exchange)YesOrdinary SharesGBGBPMay 1993
AZNOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKMay 1993
AZN NBMV (Bolsa Mexicana de Valores)SPONSORED ADRMXMXNMay 1993
0A4JLSE (London Stock Exchange)SPONSORED ADRGBUSDMay 1993
ZEGDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 1993
ZEGADB (Deutsche Boerse AG)SPONSORED ADRDEEURMay 1993
AZNSBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBSEKMay 1993
ZEGXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURMay 1993
000982352BRSE (Berne Stock Exchange)YesOrdinary SharesCHCHFMay 1993
AZNLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPMay 1993
AZN1 NBMV (Bolsa Mexicana de Valores)YesOrdinary SharesMXMXNMay 1993
ZEGBUL (Bulgaria Stock Exchange)YesOrdinary SharesBGEURMay 1993
AZNAWBAG (Wiener Boerse AG)SPONSORED ADRATEURMay 1993
AZNBASE (Buenos Aires Stock Exchange)CEDEAR EACH REP 0.5 ADR USD0.25ARARSDec 2003
AZNDBASE (Buenos Aires Stock Exchange)CEDEAR EACH REP 0.5 ADR USD0.25ARUSDDec 2003
A1ZN34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 6 REPR 1 ADRBRBRLSep 2022

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2024/12/17 09:09
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 09:09
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AstraZeneca PLC is covered by 80 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter AnkersenABG Sundal Collier
Kamla SinghAlphaValue
John EadeArgus Research Company